Article type:
Case Reports
Article
title: Valproic
acid-associated pancytopenia: a dose-dependent adverse effect
Journal: Romanian
Journal of Neurology
Year: 2019
Authors: Jamir Pitton Rissardo, Ana LetÃcia Fornari
Caprara, Juliana Oliveira Freitas Silveira
E-mail: jamirrissardo@gmail.com
ABSTRACT
Pancytopenia (PCP) is a
life-threatening condition which is rarely associated with valproic acid (VPA).
We present a case of an adult female with epilepsy that was seizure-free for
the last three years. She was in use of VPA 500 mg bid. The subject reported
that she recently had new seizures. VPA dose was increased to 500mg tid.
One-month later, she was asymptomatic and seizure-free. Laboratory tests showed
PCP. VPA dose was decreased to 500mg bid and maintained. One-month later, the
complete blood cell count was normal. After one-year, the patient reported new episodes
of convulsion. VPA was increased to 500 mg tid. One-month later, the laboratory
tests revealed PCP. Valproic acid was discontinued. Carbamazepine 200 mg tid
was started. After two-months, the laboratory tests were normal. The subject
was seizure-free and asymptomatic for the last year.
Keywords: Headache, intracranial hypertension, levofloxacin, quinolones
Full text
available at:
Citation
Rissardo JP, Caprara AL, Silveira JO. Valproic acid-associated pancytopenia: a dose-dependent adverse effect. Rom J Neurol 2019;18:150-3
